GlobeNewsWire
22 Jun 2026, 05:00 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Addex Therapeutics' partner, Indivior, has successfully completed IND enabling studies for a GABAB PAM drug candidate for substance use disorders. — Successful completion of IND enabling studies is a critical regulatory milestone that brings a drug candidate closer to human clinical trials.
+0.60The GABAB PAM chronic cough candidate is progressing toward clinical trials after showing robust anti-tussive activity in multiple disease models. — Positive preclinical data for a specific indication increases the probability of clinical success and future licensing or commercial value.
+0.40Addex Therapeutics will report its First Quarter 2026 financial results and provide a business update on June 25, 2026. — Scheduled earnings calls typically cause short-term volatility based on financial health and management guidance.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company successfully completed IND enabling studies for a GABAB PAM drug candidate.
The company is announcing financial results and reporting positive progress on drug candidates for chronic cough and brain injury.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
12m ago
